{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:40:49Z","timestamp":1791124849158,"version":"4.1.0"},"reference-count":26,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council, Singapore","doi-asserted-by":"crossref","award":["NMRC 006\/2016-00"],"award-info":[{"award-number":["NMRC 006\/2016-00"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Asia Cornea Foundation","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2025,11,6]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the effectiveness of atropine 0.01% in young premyopic and low-myopic children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Children (5\u20139 years old) with premyopia (spherical equivalent refraction, SER+1.00\u2009to \u22120.49D, n 156) or low myopia (SER \u22120.50 to \u22121.50D, n 52), with at least 1 parent with myopia &lt;\u22123.00D, were randomised to receive placebo or atropine 0.01% eye-drops in a 1:1 ratio. Cycloplegic autorefraction and axial length were measured every 6 months over 2 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean baseline SER was +0.5+\/\u22120.04D in premyopia and \u22121.00\u00b10.06D in the low-myopia eyes. Progression over 2 years in premyopic eyes was \u22120.96\u00b10.10D vs \u22120.82\u00b10.10D (p=0.328), or 0.72\u00b10.03\u2009mm vs 0.63\u00b10.04\u2009mm (p=0.161) in the placebo and atropine groups, respectively. Progression in eyes remaining emmetropic was \u22120.43\u00b10.37D vs \u22120.29\u00b10.37D (p=0.007) or 0.49\u00b10.22\u2009mm vs 0.41\u00b10.38\u2009mm (p=0.209) in the placebo versus atropine-treated eyes, respectively; while eyes which became myopic progressed by \u22121.78\u00b10.82D vs \u22121.63\u00b10.82D (p=0.121) or 1.08\u00b10.34\u2009mm vs 0.96\u00b10.14\u2009mm (p=0.010). Incident myopia at 2 years was 42.6% in placebo and 44.8% in atropine 0.01% treated eyes (p=0.896). In the low-myopia group, placebo versus atropine treated eyes progressed by \u22121.65\u00b10.15D vs \u22121.23\u00b10.15D (p=0.066) or 0.86\u00b10.07\u2009mm vs 0.68\u00b10.05\u2009mm (p=0.062) at 2 years. There was no difference in near acuity, glare (2.7%) or allergy (6.0%) between treatment groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although there were no significant differences in myopia progression between atropine and placebo treated eyes, there were trends towards less myopic shift in atropine-treated eyes in premyopic eyes which remained emmetropic and in eyes with low myopia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjo-2025-328221","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T09:15:26Z","timestamp":1773998126000},"page":"356-362","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of low-dose atropine on young premyopic and low-myopic children: atropine treatment of myopia (ATOM3) \u2013 a randomised control trial"],"prefix":"10.1136","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-4575","authenticated-orcid":false,"given":"Audrey","family":"Chia","sequence":"first","affiliation":[{"name":"Singapore National Eye Centre, Singapore"},{"name":"Singapore Eye Research Institute, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Burkill","sequence":"additional","affiliation":[{"name":"Singapore Clinical Research Institute, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Ling","sequence":"additional","affiliation":[{"name":"Singapore National Eye Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Long","family":"Quah","sequence":"additional","affiliation":[{"name":"Singapore National Eye Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Tan","sequence":"additional","affiliation":[{"name":"Singapore National Eye Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Ann","family":"Tay","sequence":"additional","affiliation":[{"name":"Singapore National Eye Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Tay","sequence":"additional","affiliation":[{"name":"Singapore Eye Research Institute, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7166-796X","authenticated-orcid":false,"given":"Seang-Mei","family":"Saw","sequence":"additional","affiliation":[{"name":"Singapore Eye Research Institute, Singapore"},{"name":"Duke-NUS Medical School, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald Tiang-Hwee","family":"Tan","sequence":"additional","affiliation":[{"name":"Singapore National Eye Centre, Singapore"},{"name":"Singapore Eye Research Institute, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,7]]},"reference":[{"key":"2026032002151780000_110.4.356.1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307724"},{"key":"2026032002151780000_110.4.356.2","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.62.5.2","article-title":"IMI Impact of Myopia","volume":"62","author":"Sankaridurg","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026032002151780000_110.4.356.3","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.62.5.3","article-title":"IMI Risk Factors for Myopia","volume":"62","author":"Morgan","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026032002151780000_110.4.356.4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.47102\/annals-acadmedsg.V46N6p229","article-title":"An Ecologic Study of Trends in the Prevalence of Myopia in Chinese Adults in Singapore Born from the 1920s to 1980s","volume":"46","author":"Sensaki","year":"2017","journal-title":"Ann Acad Med Singap"},{"key":"2026032002151780000_110.4.356.5","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-0565"},{"key":"2026032002151780000_110.4.356.6","doi-asserted-by":"publisher","DOI":"10.1111\/opo.12305"},{"key":"2026032002151780000_110.4.356.7","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-25958"},{"key":"2026032002151780000_110.4.356.8","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.62.5.6","article-title":"IMI Prevention of Myopia and Its Progression","volume":"62","author":"Jonas","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026032002151780000_110.4.356.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.07.031"},{"key":"2026032002151780000_110.4.356.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.05.062"},{"key":"2026032002151780000_110.4.356.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.24162"},{"key":"2026032002151780000_110.4.356.12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4103\/ijo.IJO_1462_21","article-title":"Efficacy of low-concentration atropine (0.01%) eye drops for prevention of axial myopic progression in premyopes","volume":"70","author":"Jethani","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"2026032002151780000_110.4.356.13","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1007\/s00431-023-04921-5","article-title":"Prevention of myopia shift and myopia onset using 0.01% atropine in premyopic children - a prospective, randomized, double-masked, and crossover trial","volume":"182","author":"Wang","year":"2023","journal-title":"Eur J Pediatr"},{"key":"2026032002151780000_110.4.356.14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/jop.2009.0135","article-title":"Prevention of myopia onset with 0.025% atropine in premyopic children","volume":"26","author":"Fang","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"2026032002151780000_110.4.356.15","doi-asserted-by":"publisher","DOI":"10.1111\/opo.12812"},{"key":"2026032002151780000_110.4.356.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.05.029"},{"key":"2026032002151780000_110.4.356.17","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/APO.0000000000000609","article-title":"Atropine Ophthalmic Solution to Reduce Myopia Progression in Pediatric Subjects: The Randomized, Double-Blind Multicenter Phase II APPLE Study","volume":"12","author":"Chia","year":"2023","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"2026032002151780000_110.4.356.18","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","article-title":"Safety and Efficacy of Low-Dose Atropine Eyedrops for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical Trial","volume":"138","author":"Wei","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"2026032002151780000_110.4.356.19","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-021-00822-y"},{"key":"2026032002151780000_110.4.356.20","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14148"},{"key":"2026032002151780000_110.4.356.21","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1080\/02713683.2022.2162925","article-title":"Low Dose Atropine in Preventing the Progression of Childhood Myopia: A Randomised Controlled Trial","volume":"48","author":"Sharma","year":"2023","journal-title":"Curr Eye Res"},{"key":"2026032002151780000_110.4.356.22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","article-title":"Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial","volume":"141","author":"Repka","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"2026032002151780000_110.4.356.23","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.071118"},{"key":"2026032002151780000_110.4.356.24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/aos.14545","article-title":"Comparison of myopic progression in Finnish and Singaporean children","volume":"99","author":"P\u00e4rssinen","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"2026032002151780000_110.4.356.25","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.ajo.2015.01.029","article-title":"Risk factors for progressive myopia in the atropine therapy for myopia study","volume":"159","author":"Loh","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"2026032002151780000_110.4.356.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.12.036"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2025-328221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T09:15:51Z","timestamp":1773998151000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2025-328221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,7]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,3,20]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bjo-2025-328221"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2025-328221","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,7]]}}}